Stock screenerAll disclosures →
EDGAR →
DRMA
Conviction 0HealthcareScan · Wed, Oct 14, 2026Dermata Therapeutics, Inc. (DRMA) closed at $0.6148 (-28.50%) on Oct 14, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 15, RS Rating 3, -85.8% from its 52-week high, -71.8% year to date. Sector: Healthcare · Pharmaceutical Preparations.
DRMA$0.6148-28.50%
ResistanceSupportVol 14Price chart, 63 bars from Fri, Jul 17, 2026 to Wed, Oct 14, 2026. Last close $0.6148, high $1.72, low $0.6148.
Vol MA14 51.18K
Jul 17Aug 4Aug 21Sep 9Sep 28Oct 14
Price0.6148
Change-28.50%
Gap-3.43%
Rel volume—
Avg volume43.82K
Avg $ vol37.35K
SMA 201.07
SMA 501.22
SMA 2001.39
Price vs 50-49.55%
Price vs 200-55.91%
MA stackbearish
50/200 cross—
Supertrenddown · 0.9945
RSI (14)15
MACD hist-0.04
MACD crossbear · 3d
Stoch %K / %D0 / 2
ADX (14)17
+DI / −DI10 / 46
RSI divergenceBullish
MACD divergenceBullish
ATR %14.73%
ADR %7.31%
52w high4.32
52w low0.6148
From 52w high-85.77%
Above 52w low+0.00%
New 52w highNo
SqueezeOff
Bollinger width49.41%
%B-0.36
Donchian pos0.00%
Donchian high1.25
Donchian low0.6148
AVWAP (52w high)1.82
vs AVWAP high-66.28%
AVWAP (52w low)0.6867
vs AVWAP low-10.47%
OBV trendDown
Chaikin MF (20)-0.72
Today vs 20d—
Avg vol (14d)51.18K
Avg vol (20d)43.82K
Avg $ vol (20d)37.35K
Market cap2.47M
RS Rating3 / 99
RS 3m (vs SPY)-54.49%
RS 6m (vs SPY)-61.17%
RS line new highNo
Trend template0/8
Technical rank4.9
1 week-45.11%
1 month-45.59%
3 months-51.97%
6 months-51.21%
1 year-85.43%
YTD-71.80%
P/E-0.33
P/B0.71
P/S—
P/FCF—
EPS-8.16
Div yield—
ROE-216.72%
ROA-142.06%
Debt/Eq0.00
Current3.40
EV/EBITDA—
Gross margin—
Net margin—
Rev growth—
EPS growth38.49%
Price target—
Target upside—
Analyst rating—
Institutional—
Ent. value-1.94M
Revenue—
Net income-2.97M
Gross profit—
Free cash flow—
IndustryPharmaceutical Preparations
ExchangeNasdaq
Shares out4.02M
Employees9
ListedFri, Aug 13, 2021
Free float3.09M
Float %76.7%
Short interest167.25K
Days to cover1.2d
Short volume22.5%
Squeeze score17 / 100
Next earnings—
EPS forecast—
Last EPS vs est—
Last surprise—
Setup gradeD
Conviction0 / 100
Pattern quality—
Tech rank4.9 / 100
Group rank—
Status laneNo active setup
Setup direction—
Pattern family
Resistance1.72
Support1.06
Days since event—
Candle confirm—
Financials as of Tue, Jun 30, 2026 · quarterly.
Recent news
- Dermata reports positive results from Tome skincare study By Investing.comInvesting.com India · Thu, Oct 15, 2026
- Dermata Therapeutics Announces Positive Topline Results from Cosmetic Study Evaluating Its Tome Foundational TreatmentYahoo Finance · Thu, Oct 15, 2026
- Dermata Therapeutics (DRMA) Drops 3.34% to $0.86 as Traders Eye $0.82 Support - Low Beta Factorhttps://www.dars.gov.et/ · Wed, Oct 14, 2026
- Dermata Therapeutics, Inc.: Dividend historical data and projectionsmarketscreener.com · Mon, Oct 12, 2026
Congress activity
Disclosed STOCK Act trades in DRMA
No recent disclosed trades by Congress in DRMA. STOCK Act filings can lag the trade by up to 45 days.
Insider activity
SEC Form 4 transactions in DRMA
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Van Hoose Kyri K. SVP, CFO · Common Stock · 2026-08-16 | Grant | 102.04K | — | 2026-08-16 | 2026-08-18 |
Van Hoose Kyri K. SVP, CFO · Series E Warrant (Right to Buy) · 2026-08-16 | Grant | 102.04K | — | 2026-08-16 | 2026-08-18 |
Van Hoose Kyri K. SVP, CFO · Series F Warrant (Right to Buy) · 2026-08-16 | Grant | 102.04K | — | 2026-08-16 | 2026-08-18 |
PROEHL GERALD T PRESIDENT, CHAIRMAN, CEO · Common Stock · 2026-08-16 | Grant | 170.07K | — | 2026-08-16 | 2026-08-18 |
PROEHL GERALD T PRESIDENT, CHAIRMAN, CEO · Series E Warrant (Right to Buy) · 2026-08-16 | Grant | 1.36M | — | 2026-08-16 | 2026-08-18 |
PROEHL GERALD T PRESIDENT, CHAIRMAN, CEO · Series F Warrant (Right to Buy) · 2026-08-16 | Grant | 1.36M | — | 2026-08-16 | 2026-08-18 |
PROEHL GERALD T PRESIDENT, CHAIRMAN, CEO · Series E Warrant (Right to Buy) · 2026-08-16 | Grant | 170.07K | — | 2026-08-16 | 2026-08-18 |
PROEHL GERALD T PRESIDENT, CHAIRMAN, CEO · Series F Warrant (Right to Buy) · 2026-08-16 | Grant | 170.07K | — | 2026-08-16 | 2026-08-18 |
PROEHL GERALD T PRESIDENT, CHAIRMAN, CEO · Pre-Funded Warrant (Right to Buy) · 2026-08-16 | Grant | 1.36M | — | 2026-08-16 | 2026-08-18 |
SEC filings
EDGAR filings in DRMA · 6 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.
Start free — 14-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.